Safety and Performance Evaluation of a Biological Matrix Used for Rectal Prolapse Repair by Ventral Rectopexy

Observational Prospective Study of a Non-cross-linked Porcine Acellular Dermal Matrix in Ventral Mesh Rectopexy

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS Rectopexy membrane used in rectal prolapse repair by ventral rectopexy and to identify emerging risks in comparison to the clinical data related to other types of fixation material.

The present study will be a prospective multicentric non-randomized and non-controlled trial involving 55 patients followed for 24 months. The study will be conducted in France in 3 investigational centres.

Study Overview

• Status: Completed
• Conditions: Rectal Prolapse
• Intervention / Treatment: Device: CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)

Detailed Description

The study will be prospective, multicentric, single-arm, observational (non-interventional) to evaluate the safety and performance of CELLIS Rectopexy used in rectal prolapse repair by ventral rectopexy.

All evaluations will be performed and products used according to the usual practice, without additional or unusual diagnostic, treatment and monitoring procedure.

The study will be conducted in France in 3 investigational centres including 55 patients scheduled for the repair of rectal prolapse.

Each patient will participate in one assessment period including a screening visit, followed by the day of surgical procedure and a hospitalization period. Patients will return for ambulatory visits at Day 30 (+/- 7 days), Month 6 (+/- 2 weeks), Month 12 (+/- 2 weeks) and Month 24 (+/-2 weeks).

The surgical technique used to repair rectal prolapse will be either Laparoscopic Ventral Rectopexy (LVR) or a robotic assisted rectopexy with the use of the da Vinci Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA).

• Study Type: Observational
• Enrollment (Actual): 55

Contacts and Locations

Study Locations

• France
  • Clermont-Ferrand, France, 63 003
    • Chu Estaing
  • Nantes, France, 44 093
    • CHU Nantes Hôtel Dieu
  • Pessac, France, 33 604
    • Hôpital Haut-Lévèque- CHU de Bordeaux

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Constitution and follow-up of a consecutive cohort of patients operated with the CELLIS Rectopexy membrane based on the usual practices, the indication and the inclusion-exclusion criteria.

Description

Inclusion Criteria:

• Patient aged ≥18 years,
• Patient with an indication of rectal prolapse repair by ventral rectopexy (external and internal rectal prolapse),
• Patient being informed of its participation to the study and of the follow-up visits, and having no objection to the clinical data collection and medical file access,
• Patient being informed of the porcine origin of the device in advance of the procedure.

Exclusion Criteria:

• Patient with known hypersensitivity to porcine materials,
• Patient with an existing infection not appropriately treated,
• Patient who are pregnant,
• Patient having refused to participate to the study,
• Patient refusing to come back to the follow-up visits.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
CELLIS Rectopexy; Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix	Device: CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM); Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of adverse events including reoperation and removal of the mesh	Percentage	From the surgical procedure through the entire 24-month follow-up period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Description of device deficiency: inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors, and inadequate labelling.	Summarized and listed	During the surgical procedure
Rate of structural defect recurrence based on rectal examination with/without adjunctive investigations as clinically indicated	Percentage	Throughout the study until end of the 24-month follow-up period
Rate of structural defect recurrence requiring reoperation	Percentage	Throughout the study until end of the 24-month follow-up period
Symptoms evolution: presence or absence of symptoms (constipation, fecal incontinence, bloody and/or mucous rectal discharge (soiling), unsatisfactory sexual activity, pain)	Described at each visit and compared to baseline	At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits
Symptoms severity scored by a visual analog scale (0-10; 0 corresponding to no impact on life and 10 corresponding to extreme, incapacitating impact)	Described at each visit and compared to baseline	At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits
Rate of symptoms recurrence	Percentage	Throughout the study until end of the 24-month follow-up period
Severity of disease by the use of the Cleveland Clinic Incontinence Score (CCIS)	Change from screening of total score at each follow-up visit. This scoring system cross-tabulates frequencies and different anal incontinence presentations (Gas/Liquid/Solid/Pad use/Need for lifestyle alterations) and sums the returned score to a total of 0-20 (where 0 = perfect continence and 20 = complete incontinence).	At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits
Severity of disease by the use of the Obstructed Defecation Score (ODS)	Change from screening of total score at each follow-up visit. The ODS score is the sum of all points, with a minimum of 0 point and a maximum possible of 31 points with higher scores meaning worse outcome.	At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits
Quality of life by the use of the Short Form (36) Health Survey (SF-36) questionnaire	Change from screening of each domain score and total score at 24-month. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 with lower scores = more disability, and higher scores = less disability	At baseline and at 24-month

Collaborators and Investigators

• Sponsor: Meccellis Biotech
• Investigators: Principal Investigator: Guillaume MEURETTE, MD, CHU Nantes, France

Study record dates

Study Major Dates

• Study Start (Actual): December 11, 2019
• Primary Completion (Actual): October 26, 2023
• Study Completion (Actual): October 26, 2023

Study Registration Dates

• First Submitted: October 14, 2019
• First Submitted That Met QC Criteria: October 15, 2019
• First Posted (Actual): October 17, 2019

Study Record Updates

• Last Update Posted (Actual): October 27, 2023
• Last Update Submitted That Met QC Criteria: October 26, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: biological mesh; ventral rectopexy
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Pathological Conditions, Anatomical; Rectal Diseases; Pelvic Organ Prolapse; Prolapse; Rectal Prolapse
• Other Study ID Numbers: RPR_01_CIP; 2019-A02024-53 (ID-RCB) (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No